The Economic Times recently reported that the Government of India is considering a set of proposals by global drugmakers that seeks certain changes in the country’s IP regime that can compromise Indian drugmakers ability to sell low-cost medicines.

The Prime Ministers’s office (PMO) has sought views from the ministry of commerce, health & family welfare and department of legal affairs on the proposals. As per the PMO note, the proposals include changes in controversial matters such as ‘legislative review’ of the section 3(d) of the Indian patents Act and clearly redefining ‘efficacy criteria.’

Section 3(d) of the Indian Patent Act [...]

OUVRIR MON COMPTE CREATE MY ACCOUNT

  Un problème avec cet article ? / A problem with this article?